Form 8-K - Current report:
SEC Accession No. 0001213900-26-052542
Filing Date
2026-05-06
Accepted
2026-05-06 08:05:42
Documents
13
Period of Report
2026-05-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0289243-8k_allarity.htm   iXBRL 8-K 22995
2 PRESS RELEASE, DATED MAY 5, 2026 ea028924301ex99-1.htm EX-99.1 28354
3 GRAPHIC ea028924301_ex99-1img1.jpg GRAPHIC 13161
  Complete submission text file 0001213900-26-052542.txt   240974

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE allr-20260505.xsd EX-101.SCH 3014
5 XBRL LABEL FILE allr-20260505_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE allr-20260505_pre.xml EX-101.PRE 22358
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0289243-8k_allarity_htm.xml XML 3213
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 26945896
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)